Three kinds of drug-eluting bead transarterial chemoembolisation for treating patients with unresectable non-small cell lung cancer

Table 2 Technical outcomes and complication s of rug-eluting bead transarterial chemoembolization, n (%)/mean ± SD/median (25^th-75^th percentiles)

	DOX group (n = 64)	OXA group (n = 44)	GEM group (n = 61)	P value
Initial technical success	63 (98.4)	42 (95.5)	59 (96.7)	0.66
Procedure time (minute)	85.0 (70.0-120.0)	90.0 (60.8-111.3)	93.0 (60.0-118.0)	1.00
Hospital day	14.5 (10.8-20.0)	11.0 (8.0-17.0)	14.0 (10.0-19.5)	0.12
Total cost of hospitalization, × 104 (¥)	6.6 ± 2.2	6.2 ± 2.1	6.9 ± 1.9	0. 35
Session of DEB-TACE	1.4 ± 0.6	1.6 ± 1.0	1.3 ± 0.6	0.22
I125 seed implantation	15 (31.9)	2 (6.9)	15 (31.9)	< 0.01
Thermal ablation	5 (10.6)	0 (0.0)	0 (0.0)	0.01
cTACE	9 (19.1)	5 (17.2)	7 (14.9)	0.86
TAE for hemoptysis	6 (12.8)	1 (3.4)	4 (8.5)	0.38
DEB-TACE for liver or renal metastasis	1 (2.1)	5 (17.2)	1 (2.1)	< 0.01
Esophageal or airway stenting	6 (12.8)	1 (3.4)	4 (8.5)	0.38
Vascular stent implantation	1 (2.1)	0 (0.0)	2 (4.3)	0.50
Complications1	19 (40.4)	10 (34.5)	15 (31.9)	0.63
Fever	3 (6.4)	2 (6.9)	3 (6.4)	1.00
Nausea or vomiting	8 (17.0)	4 (13.8)	5 (10.6)	0.67
Chest pain	8 (17.0)	5 (17.2)	6 (12.8)	0.81
Pain of access site	2 (4.3)	0 (0.0)	2 (4.3)	0.53
Others	1 (2.1)	1 (3.4)	3 (6.4)	0.57

¹Some patients experienced more than one adverse event.

DOX: Doxorubicin; OXA: Oxaliplatin; GEM: Gemcitabine; cTACE: Conventional transarterial chemoembolisation; TACE: Transarterial chemoembolization; DEB-TACE: Drug-eluting bead transarterial chemoembolization.